Novartis Historical Financial Ratios
NVS Stock | USD 97.27 0.07 0.07% |
Novartis is lately reporting on over 102 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 76.73 will help investors to properly organize and evaluate Novartis AG ADR financial condition quickly.
Novartis |
About Novartis Financial Ratios Analysis
Novartis AG ADRFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Novartis investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Novartis financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Novartis history.
Novartis Financial Ratios Chart
Novartis AG ADR financial ratios usually calculated using numerical values taken directly from Novartis financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about Novartis. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
At this time, Novartis' Interest Coverage is comparatively stable compared to the past year. PFCF Ratio is likely to gain to 19.28 in 2024, whereas Dividend Yield is likely to drop 0.03 in 2024. Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Novartis AG ADR stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Novartis sales, a figure that is much harder to manipulate than other Novartis AG ADR multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Novartis AG ADR dividend as a percentage of Novartis stock price. Novartis AG ADR dividend yield is a measure of Novartis stock productivity, which can be interpreted as interest rate earned on an Novartis investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Most ratios from Novartis' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. At this time, Novartis' Interest Coverage is comparatively stable compared to the past year. PFCF Ratio is likely to gain to 19.28 in 2024, whereas Dividend Yield is likely to drop 0.03 in 2024.
2022 | 2023 | 2024 (projected) | Dividend Yield | 0.0401 | 0.0346 | 0.0251 | Price To Sales Ratio | 3.61 | 4.5 | 3.66 |
Novartis fundamentals Correlations
Click cells to compare fundamentals
Novartis Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novartis fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 3.13 | 4.22 | 4.08 | 3.61 | 4.5 | 3.66 | |
Ptb Ratio | 3.7 | 3.6 | 2.74 | 3.16 | 4.49 | 3.07 | |
Days Sales Outstanding | 64.15 | 61.85 | 57.18 | 58.69 | 73.34 | 76.73 | |
Book Value Per Share | 24.22 | 24.86 | 30.17 | 27.21 | 22.47 | 17.72 | |
Free Cash Flow Yield | 0.0554 | 0.0544 | 0.0652 | 0.0618 | 0.0558 | 0.0494 | |
Invested Capital | 0.53 | 0.67 | 0.46 | 0.47 | 0.56 | 0.59 | |
Operating Cash Flow Per Share | 5.95 | 5.99 | 6.72 | 6.53 | 6.96 | 3.63 | |
Capex To Depreciation | (0.49) | (0.39) | (0.4) | (0.37) | (0.33) | (0.35) | |
Pb Ratio | 3.7 | 3.6 | 2.74 | 3.16 | 4.49 | 3.07 | |
Ev To Sales | 4.59 | 4.65 | 3.86 | 4.01 | 4.77 | 2.82 | |
Free Cash Flow Per Share | 4.96 | 4.86 | 5.4 | 5.3 | 5.64 | 2.83 | |
Roic | 0.0673 | 0.0856 | 0.0876 | 0.25 | 0.0875 | 0.13 | |
Inventory Turnover | 2.41 | 2.12 | 2.38 | 2.16 | 2.11 | 1.82 | |
Net Income Per Share | 3.12 | 3.54 | 10.71 | 3.19 | 7.15 | 7.51 | |
Days Of Inventory On Hand | 151.36 | 172.13 | 153.34 | 169.11 | 173.05 | 184.62 | |
Payables Turnover | 2.66 | 2.8 | 2.86 | 3.01 | 2.53 | 4.03 | |
Capex To Revenue | (0.0464) | (0.0518) | (0.0562) | (0.0515) | (0.059) | (0.062) | |
Cash Per Share | 6.88 | 5.0 | 5.08 | 12.63 | 8.68 | 6.72 | |
Pocfratio | 15.06 | 14.91 | 12.32 | 13.15 | 14.51 | 14.92 | |
Interest Coverage | 10.69 | 11.68 | 33.23 | 10.99 | 11.43 | 20.02 | |
Pfcf Ratio | 18.06 | 18.39 | 15.34 | 16.19 | 17.92 | 19.28 | |
Days Payables Outstanding | 137.25 | 130.42 | 127.74 | 121.29 | 144.16 | 84.15 | |
Income Quality | 1.64 | 1.13 | 1.91 | 0.63 | 2.05 | 1.1 | |
Roe | 0.1 | 0.16 | 0.13 | 0.36 | 0.32 | 0.33 | |
Ev To Operating Cash Flow | 16.4 | 16.99 | 13.56 | 14.59 | 15.4 | 15.75 | |
Pe Ratio | 28.72 | 25.21 | 7.73 | 26.92 | 14.12 | 13.62 | |
Ev To Free Cash Flow | 19.66 | 20.96 | 16.88 | 17.96 | 19.03 | 20.35 | |
Earnings Yield | 0.0348 | 0.0397 | 0.13 | 0.0371 | 0.0708 | 0.0526 | |
Net Debt To E B I T D A | 1.17 | 1.65 | 0.57 | 1.25 | 0.7 | 0.47 | |
Tangible Book Value Per Share | 0.1 | (4.45) | 1.8 | (0.7) | (1.67) | (1.59) | |
Receivables Turnover | 5.69 | 5.9 | 6.38 | 6.22 | 4.98 | 4.26 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
CEOs Directory Screen CEOs from public companies around the world |
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.215 | Dividend Share 3.919 | Earnings Share 4.4 | Revenue Per Share 23.168 | Quarterly Revenue Growth 0.097 |
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.